Stelara biosimilars look to gain traction, helped by recent lessons from Humiranews2025-05-19T19:29:57+00:00May 19th, 2025|Endpoints News|
Intellia’s CRISPR therapy likely causes ‘permanent’ gene knockdown in ATTR amyloidosisnews2025-05-19T15:14:34+00:00May 19th, 2025|Endpoints News|
Novavax wins FDA approval of Covid shot after delay, with restrictionsnews2025-05-19T02:34:04+00:00May 19th, 2025|Endpoints News|
HHS can require approval for drugmakers to apply 340B rebate models, court rulesnews2025-05-16T19:38:00+00:00May 16th, 2025|Endpoints News|
FDA raises issues with four cancer drugs ahead of adcommnews2025-05-16T17:38:08+00:00May 16th, 2025|Endpoints News|
Amarin urges Supreme Court to decline Hikma’s drug label spatnews2025-05-16T16:51:33+00:00May 16th, 2025|Endpoints News|
Mark Cuban compounder joins Trump’s new manufacturing initiativenews2025-05-16T15:15:19+00:00May 16th, 2025|Endpoints News|
BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozymenews2025-05-16T15:08:49+00:00May 16th, 2025|Endpoints News|
Novo Nordisk CEO to step down, timeline for successor unknownnews2025-05-16T11:22:51+00:00May 16th, 2025|Endpoints News|
